Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01876446
Show Display Options
Rank Status Study
1 Recruiting Etirinotecan Pegol (NKTR 102) in Treating Patients With Relapsed Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Cancer
Interventions: Drug: etirinotecan pegol (NKTR 102);   Other: pharmacogenomic studies;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years